Amphastar Pharmaceuticals, Inc.

AMPH · NasdaqGS · Stock · Healthcare
$26.08
+0.12% today
Delayed price,

What Amphastar Pharmaceuticals does

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Key facts

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market cap
$1.11B
P/E (ttm)
15.4
Forward P/E
8.2
Dividend yield
0.00%
Beta
0.90
Profit margin
10.8%
Employees
1,976
Headquarters
Rancho Cucamonga, CA, United States
Exchange
NasdaqGS

Performance

1 Month
+10.4%
3 Months
+32.1%
6 Months
+14.0%
1 Year
+9.7%
5 Years
+33.3%
$16.6552-week range$29.52
Biggest setback — last 12 months
-42.3%
2 Feb 2026 → 11 May 2026
Fell from $29.26 to $16.87 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+57.8%
11 May 2026 → 5 Oct 2026
Ran from $16.87 to $26.62 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$22.87 (-12.3%)$26.08$29.74 (+14.0%)
3 Months$20.78 (-20.3%)$26.08$32.73 (+25.5%)
6 Months$18.91 (-27.5%)$26.08$35.96 (+37.9%)
12 Months$16.56 (-36.5%)$26.08$41.09 (+57.5%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 45.5%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.